The global single photon emission computed tomography (SPECT) market size is projected to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to increasing use of nuclear imaging technique that uses radioactive tracers and a scanner to record data.
SPECT scan is an imaging test that shows how blood flows through tissues and organs. SPECT is combined with computed tomography (CT) and MRI scanners to provide a detailed metabolic information of the human body. These systems are applicable in diagnosis of various diseases such as cardiac, brain, and cancer. Several types of therapeutics radioisotopes, such as iodine-123, technetium-99m, xenon-133, and thallium-201 are used along with the SPECT system for pain treatment and cell destruction procedure.
Proper calibration and operation direct the high quality results of SPECT systems. It can help in the diagnosis of seizures, stroke, stress fractures, infections, and tumors in the spine. SPECT is used in the evaluation of various diseases. Most broadly used SPECT systems are based on anger gamma cameras, which involves dual detectors that rotate around the patient.
Market Trends, Drivers, Restraints, and Opportunities
- Increasing trend of organ-specific systems, to enhance the diagnostic capability of the equipment is estimated to propel the market growth during the forecast period.
- Rising application of hybrid equipment and fused techniques has increased the importance in the imaging diagnostics field, which is projected to boost the market expansion.
- Simultaneous use of several modalities, which can give data about the morphological, functional, and molecular changes of the different diseases are estimated to spur the market growth.
- Integration of X-ray computed tomography (CT) into SPECT has emerged as an essential diagnostic tool in medical imaging, where anatomical details may delineate functional and metabolic information. Thus, such fusion of technologies is anticipated to fuel the market growth.
- Growing utilization of positron emission tomography (PET) owing to functional and morphologic correlative images is one of the key factors that can foster the market growth during the forecast period.
- High cost of reagents and side effects of radiopharmaceutical are speculated to restrict the market expansion during the forecast period.
- Sensitivity toward storage conditions can hamper the single-photon emission computed tomography (SPECT) market in the coming years.
- Increasing R&D investment and ongoing technological advancements in CT and MRI to provide detailed anatomical information are expected to offer significant opportunities for the market players in the projected timeline.
Scope of Single Photo Emission Computed Tomography (SPECT) Market Report
The report on the global single photon emission computed tomography (SPECT) market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Single Photon Emission Computed Tomography (SPECT) Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2020
|
|
Historic Data
|
2018–2019
|
|
Forecast Period
|
2021–2028
|
|
Segmentation
|
Types of Radioisotopes (Technetium-99m, Radium-223, Gallium-67, Iodine-123 and Others), Applications (Cardiology, Oncology, Neurology, and Others)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Bracco Imaging, GE Healthcare (GE Company), Curium, Cadinal Health Inc, and NTP Radioisotopes SOC Ltd.
|
Single Photon Emission Computed Tomography (SPECT) Market Segment Insights
Gallium-67 segment to hold a large market share
Based on types of radioisotopes, the market is divided into technetium-99m, radium-223, gallium-67, iodine-123, and others. The gallium-67 segment is expected to account for a key market share during the forecast period owing to its increasing usage in the diagnosis of inflammation, both acute & chronic infection and tumours, such as Hodgkin’s disease, lymphoma, hepatoma, and bronchogenic carcinoma. It is also used as a bone imaging agent.
Oncology segment is expected to register at a significant pace
In terms of applications, the market is divided into cardiology, oncology, neurology, and others. The oncology segment is expected to grow at a rapid pace during the forecast period. According to the World Health Organization (WHO), about 17.1 million new cases of cancer and approximately 8.5 million deaths were recorded in 2018. It added that one in five men and one in 6 women can develop cancer during their lifetime, and one in eight men and one in 11 women die from the disease.
North America to dominate the market
On the basis of regions, the market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market during the forecast period. The regional market growth can be attributed to the advancements in technology, including hybrid imaging as well as introduction of new radiopharmaceuticals for diagnosis and the development of molecular imaging.
Segments
The global Single Photon Emission Computed Tomography (SPECT) market has been segmented on the basis of
Types of Radioisotopes
- Technetium-99m
- Radium-223
- Gallium-67
- Iodine-123
- Others
Applications
- Cardiology
- Oncology
- Neurology
- Others
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
Competitive Landscape
Key players competing in the Single Photon Emission Computed Tomography (SPECT) market include Bracco Imaging, GE Healthcare (GE Company), Curium, Cadinal Health Inc, and NTP Radioisotopes SOC Ltd.
Request For Customization
Enquiry Before Buying
Speak With Analyst
